Insilico Medicine (“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced that four abstracts have been accepted as poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023.
Insilico will present four novel inhibitors for the treatment of cancer developed with its end-to-end Pharma.AI platform. Drawing from trillions of data points and millions of compounds and molecular fragments, the platform uses generative AI for target identification and generative chemistry to produce new molecules.
“Our oncology pipeline is growing rapidly thanks to the capabilities of our generative AI platform,” says Sujata Rao, MD, Senior VP of Clinical Development at Insilico Medicine, who will present data on the Company’s anti-cancer assets. “We’ve been able to rapidly produce and advance a number of promising potentially first-in-class and best-in-class molecules that we hope can soon bring new therapeutic options to cancer patients who are not responding to other treatments.”
Michelle Chen, PhD, Insilico Medicine’s Chief Business Officer, will also attend AACR to discuss partnering and licensing opportunities. “We are actively looking for licensing partners for multiple assets in our pipeline who can work with us to further develop these drug candidates and help cancer patients,” says Dr. Chen.
Insilico has a robust pipeline of assets in the cancer space, among other disease areas, and will showcase four programs available for partnering and out-licensing at AACR. These include:
Abstract Title: ISM3091, a novel selective USP1 inhibitor as a targeted anticancer therapy
Session category: Experimental and molecular therapeutics
Session title: Novel antitumor agents 2
Session date & time: April 16, 1:30-5pm
Published abstract number: 502
Description: ISM3091 is an orally available and selective small molecule inhibitor of USP1, and demonstrated potential when targeted against a broad range of tumor lineages with HRD backgrounds. In vitro data showed potent anti-proliferation activity of the compound in BRCA-mutant tumor cells with excellent selectivity.
Abstract Title: ISM3412, a novel and selective MAT2A inhibitor for the treatment of cancer
Session category: Experimental and molecular therapeutics
Session title: Novel antitumor agents 2
Session date & time: April 16, 1:30-5pm
Published abstract number: 503
Description: MAT2A is defined as a synthetic lethality target in MTAP-deleted cancers and plays an essential role in producing S-adenosylmethionine (SAM), a molecule involved in cell function and survival. As a potent and selective MAT2A inhibitor, ISM3412 demonstrated excellent drug-likeness with good solubility and permeability, good activity at low doses in animal models, and a favorable safety profile in preclinical studies.
Abstract Title: Targeting DGKA for immuno-oncology therapy: ISM4312A, a novel DGKA inhibitor with robust anti-tumor activity
Session category: Immunology
Session title: Immunomodulatory agents and interventions 2
Session date & time: April 17, 9am-12:30pm
Published abstract number: 1855
Description: Research indicates that DGKA mediates T-cell dysfunction during anti-PD-1 therapy, playing a role in the development of resistance to PD-1 blockade. ISM4312A is a novel DGKA inhibitor with excellent potency and high selectivity in cancer immunotherapy. The compound enhanced T-cell activity in vitro and showed robust anti-tumor activities with or without anti-PD-1 therapy in vivo. Those data support the further evaluation of ISM4312A as a potential first-in-class DGKA inhibitor both as a single agent and in combination with a checkpoint inhibitor.
Abstract Title: Discovery and evaluation of ISM6466A, a novel covalent CDK12 inhibitor for the treatment of cancer
Session category: Experimental and molecular therapeutics
Session title: Targeting protein kinases and phosphatases for therapy 1
Session date & time: April 18, 1:30-5pm
Published abstract number: 4989
Description: CDK12 inhibitors work synergistically with chemotherapy and PARP inhibitors and can be effective in a number of cancer types, including triple negative breast cancer, colorectal cancer, ovarian cancer, and hepatocellular carcinoma. Insilico’s novel inhibitor, designed by its Pharma.AI platform, capitalizes on this cancer treatment approach that relies on the induction of the “BRCAness” phenotype.
Insilico has rapidly developed its portfolio with nearly 30 assets in a variety of disease areas, including a number in the oncology space. The Company has partnered with leading pharma companies including Sanofi and Fosun Pharma to develop their programs and is actively seeking partners for its available assets.
“Leveraging AI with support from our CROs and our dedicated and experienced drug discovery team, we have been able to deliver many high-quality drug candidates,” says Insilico Medicine founder and CEO Alex Zhavoronkov, PhD. “In addition, our AI-powered robotics laboratory has the potential to take drug discovery to the next level by combining images with high content, high throughput screenings with AI to deliver the medicines of the future.”
About Insilico Medicine
Insilico Medicine, a clinical stage end-to-end generative artificial intelligence (AI)-driven drug discovery company, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com
